Larvol Delta - Avenzo-Therapeuticsreported-updated-clinical-data-from-the-Phase-1-portion-of-its-ongoing-Phase-12-clinical-study-of-AVZO021-its-potentially-differentiated-cyclindependent-kinase-2-CDK2-selective-inhibitor

AVZO-021 - Avenzo Therap

https://www.businesswire.com/news/home/20260601127731/en/Avenzo-Therapeutics-Presents-Updated-Results-from-the-Phase-12-Study-of-AVZO-021-a-Potentially-Differentiated-CDK2-Inhibitor-at-the-2026-American-Society-of-Clinical-Oncology-Annual-Meeting

Jun 1, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next